Vascular cell procoagulant activity may be important in the pathogenesis of atherosclerosis. In previous studies, we described the ability of the atherogenic metabolite homocysteine to activate endothelial cell Factor V, a key coagulation cofactor for thrombin generation. The present study was designed to investigate Factor V activity and Factor X.-catalyzed prothrombin activation by control and atherosclerotic aorta from normal and hypercholesterolemic rabbits. Factor X. generated ninefold more thrombin on atherosclerotic aortic segments than on control segments. Atherosclerotic segments activated '25I-prothrombin with Factor X. in the presence of the thrombin inhibitor dansyl arginine4-ethylpiperidine amide and cleaved 125I-Factor V. This suggests that increases in vessel-wall Factor V activity and Factor X.-catalyzed prothrombin activation result from activation of vessel-wall Factor V. 125I_ Factor V. peptides generated by atherosclerotic aorta were very similar in molecular weight to those generated by homocysteine-treated cells. When vascular endothelium was mechanically removed by brushing, atherosclerotic vessels still generated four-to fivefold more thrombin than control vessels. These data and results from immunocytochemical studies suggest that Factor V in atherosclerotic vessels is associated with both endothelium and other cells of the lesion. In contrast, Factor V in control vessels is associated primarily with endothelium. The increases in Factor V activity and thrombin formation in the blood vessel wall of hypercholesterolemic rabbits may contribute to the development of atherosclerosis and its complications.
Introduction
Endothelial cell injury is postulated to initiate atherosclerosis (1) . Two conditions associated with atherosclerotic vascular disease are elevated serum levels of cholesterol (2) or homocysteine (3) . In a previous study, we reported that homocysteine-treated endothelial cells exhibited increased procoagulant activity (4) as a result of activation of endogenous Factor V. Factor Va associated with cellular surfaces serves as the receptor for Factor Xa; formation of the Factor Va-Factor Xa complex results in the activation of prothrombin to the coagulation protease thrombin (5) . The ability of perturbed endothelial cells to activate this important coagulation cofactor resulted in enhanced Factor Xa-catalyzed prothrombin activation and increased generation of thrombin (4) . Thrombin formation is important, not only in the generation of fibrin, but also in the amplification of the coagulation mechanism (6) .
These data led us to consider whether hypercholesterolemia would induce similar changes in vascular procoagulant activity, since exposure of endothelium to high concentrations of atherogenic lipoproteins (modified LDL and , re- sults in abnormal endothelial cell morphology (7, 8) . In fact, specific receptors for modified LDL (9) and ,B-VLDL (10) have been identified on cultured endothelium. Perturbation of endothelial cells by other stimuli, including endotoxin (1 1) and IL-1 (12), has been demonstrated to induce expression of procoagulant (tissue factor) activity. Expression of vascular procoagulant activity may, therefore, occur in hypercholesterolemia, leading to thrombin generation. Thrombin has been demonstrated to cause monocyte chemotaxis (13) and mitogenesis (14), endothelial cell retraction (15) , and release of endothelial cell mitogens (16) , events that could be involved in atherogenesis. Thus, thrombin may contribute to the development of the atherosclerotic lesion.
One approach to the study of atherogenic stimuli and endothelial cell procoagulant properties is to use an animal model of atherosclerosis. Although there are limitations in extrapolating from data obtained in these in vivo models to human atherosclerosis, certain animal models of hyperlipidemia have provided important information relevant to the human form of this disorder (1, (17) (18) (19) (20) . In this study, we used a rabbit model of diet-induced atherosclerosis to investigate vessel-wall procoagulant properties. In particular, Factor V activity and Factor Xa-catalyzed prothrombin activation in thoracic aorta from control and hypercholesterolemic animals were examined. These coagulant properties were previously noted to be enhanced after in vitro exposure of endothelial cells to the atherogenic stimulus homocysteine (4 Factor X and prothrombin were purified from human plasma as described (21). Human Factor V was purified according to the methods ofKane and Majerus (22). Bradford's technique was followed to assay protein concentrations (23) . Prothrombin and Factor V were iodinated using the lodogen technique (22) . Standard clotting assays were used to measure Factor X activity (24) , and Factor X was activated using Russell's Viper venom coupled to Sepharose (25) . Normal rabbit plasma was obtained by venipuncture using an anticoagulant solution containing 3.8% sodium citrate, 10 mM benzamidine, and 0.1 mM PMSF.
Hypercholesterolemic rabbit model. Male New Zealand White rabbits (3-3.5 kg) were fed either a standard diet (control: rabbit chow, Zeigler Brothers, Inc., Gardners, PA) or an atherogenic diet containing 0.5% cholesterol (NIH Zeigler 700-79) for 12-16 wk (26). 10 control rabbits and 10 rabbits on the high-cholesterol diet for this period were studied. Aortas from control and hypercholesterolemic rabbits were obtained after anesthesia and exsanguination. Atherosclerotic aorta generally exhibited diffuse fatty streak lesions, and the involved thoracic segments were taken for assay. Control segments were taken from similar locations of normal aorta. The vessels were placed in warmed, sterile DME containing 1% BSA.
Vessel-wall coagulation assays. Coagulant properties of the vessels were assessed using a Lucite template device (exposed vessel surface area -0.75 cm2), similar to that previously used by our laboratory to study prothrombin activation by bovine vessels and Factor X. (27) . In this prothrombin activation assay, the following additions were made to the template well: 0.4 ml of warmed 20 mM Tris-HCl, 150 mM NaCl (Tris-buffered saline [TBS]), pH 7.4; 35 Mg of purified prothrombin; and 0.05 ml of 100 mM CaCl2. The reaction was initiated by adding 10 ng of Factor X.. Total reaction volume was 0.5 ml. At intervals, aliquots were removed for thrombin assay (28) . Replicate values obtained by this assay varied by ±10% (SEM).
To determine whether vascular tissue not exposed to template manipulation had similar coagulant properties, aortic arches were obtained from control and hypercholesterolemic rabbits. These segments were gently washed with medium to remove blood. The major blood vessels originating from the aortic arch and the root of the aorta were ligated to form a small pouch 1-1.5 cm long. Prothrombin activation by these vessels and Factor X. was assayed in the vessel segment by using 20% of the amounts of the components listed above; total volume was 0.1 ml. Thus, similar concentrations ofreactants were used in studies with the template device and with aortic pouches.
Immunocytochemical techniques. Cross-reactivity between the anti-human Factor V IgG and rabbit Factor V was demonstrated by immunoblotting (29) . Purified human Factor V and normal rabbit plasma were subjected to 5% nonreduced SDS-PAGE. Separated proteins were transferred to nitrocellulose filter paper. Two methods were used to determine whether atherosclerotic vessel segments contained Factor V. activity. In the first method, cleavage of '25I-prothrombin by Factor X. and either control or hypercholesterolemic aortic segments was determined in the presence or absence of the thrombin inhibitor DAPA (100 gM). The rationale for these experiments is that Factor X. cannot cleave 125I-prothrombin in the presence of a thrombin inhibitor unless Factor V has been activated. Factor X., aliquots of the incubation were removed at intervals, subjected to nonreduced SDS-PAGE, dried, and processed for autoradiography (25) to determine the extent of '23I-prothrombin cleavage.
The second method was used to determine whether atherosclerotic vessel segments were able to activate exogenous Factor V. 300 ng of freshly prepared '25I-Factor V was added to 1 l-cm2 control or hypercholesterolemic aortic segments in 0.5 ml of DME-BSA. At intervals, the medium was removed and 0.1 ml of reduced SDS-gel buffer was added to the segments. Solubilized material associated with the vessel segments was analyzed by reduced SDS-PAGE and autoradiography.
Lipoprotein studies. Human LDL was isolated from normal plasma as described (34) , and the lysine residues were modified by acetoacetylation with diketene (35) . Hyperlipoproteinemic plasma was obtained from cholesterol-fed rabbits for isolation of fl-VLDL (35) . To determine whether purified lipoproteins could affect Factor V activity of cultured endothelial cells, purified native and modified lipoproteins were incubated with confluent ABAE cells for 3-48 h in serum-free medium. The cells were processed as described for determination of Factor V activity (4).
Results
Factor Xa-catalyzed prothrombin activation by atherosclerotic aorta. Rabbits that had been fed a diet containing 0.5% cholesterol for 12-16 wk were routinely studied. As a result ofthis diet, serum cholesterol levels were > 1,000 mg/dl at this time, and typical fatty streak atherosclerotic lesions ofthe aorta were grossly visible. In contrast, serum cholesterol levels in control 1912 G. M. Rodgers, W. H. Kane, and R. E. Pitas rabbits were < 100 mg/dl and no evidence of atherosclerotic disease was present, as determined by histologic examination.
Two methods were used to examine Factor X5-catalyzed prothrombin activation by atherosclerotic aortic segments. In one study, vessel segments were placed in a template device to conduct incubations; in the other method, an intact aortic arch was obtained and the reactions were conducted within the aortic lumen. Fig. 1 depicts a typical time course of thrombin generation by control and atherosclerotic vessels in the template device. Incubation mixtures included purified prothrombin, Factor X., and calcium. Typically, prothrombin activation by atherosclerotic vessels was enhanced eight-to ninefold over that produced by control vessels. Omission of Factor X. or substitution ofthe zymogen, Factor X, resulted in a failure ofthe vessel segments to activate prothrombin. Thus, prothrombin activation by atherosclerotic vessels occurred via the Factor Va-Factor X. pathway, and not by an activator of Factor X or prothrombin.
Experiments with aortic arch segments were conducted to ensure that the enhanced prothrombin activation was not an artifact that resulted from placing the vessel segments flat in the template device. These aortic arch segments obtained from hypercholesterolemic animals also activated nine times more prothrombin than did control aortic arches (data not shown), which demonstrated that the enhanced prothrombin activation was not an artifact.
The duration of hypercholesterolemia required for enhanced aortic Factor X5-catalyzed prothrombin activation was also investigated. In these studies, we measured Factor X,-catalyzed prothrombin activation by aortic segments from rabbits on the diet for 5 d, 12 d, 4 wk, 5 wk, and 6 wk. As in other experiments, vessel segments were selected from similar areas of the thoracic aorta. Aortic segments from some animals on the diet 4 wk had visible fatty streaks, but they did not generate more thrombin than control segments. In contrast, after 5 wk of hypercholesterolemia, atherosclerotic vessels routinely exhibited increased prothrombinase activity. In two rabbits that had been on the high-cholesterol diet for 14 wk, focal atherosclerotic lesions of the thoracic aorta were present instead of the diffuse lesions commonly observed.
Assays ofFactor X.-catalyzed prothrombin activation by these aortic segments revealed increased activity only in involved areas; assays using what grossly appeared to be uninvolved aortic segments generated a level of thrombin very similar to [ that seen in control aortic segments. The inability to detect thrombin generation by vessel segments either from hypercholesterolemic animals on the diet for < 4 wk or from focally uninvolved vessel segments may reflect insensitivity of our thrombin time assay to low concentrations of thrombin (the lower limit of detection was -0.5 U/ml).
Experiments were also performed with segments of superior vena cava from control and hypercholesterolemic rabbits; atherosclerotic plaques were sometimes observed in this venous tissue of hypercholesterolemic rabbits. Factor X.-catalyzed prothrombin activation by vena-caval segments was enhanced threefold compared with that seen with control venous segments.
Factor V (Va) activity of atherosclerotic aorta. Although our human anti-Factor V IgG could immunologically detect rabbit Factor V, it did not neutralize rabbit Factor V coagulant activity. Therefore, to correlate increased aortic Factor X5-catalyzed prothrombin activation with vessel-wall Factor V activity, punch biopsy samples from control and atherosclerotic aortic segments were obtained from five rabbits of each group, and Factor V (V.) activity was measured by clotting assay (Table I) . Atherosclerotic segments were diffusely involved with lesion. Compared with control aortic segments, atherosclerotic aortic biopsy samples possessed approximately threeto fourfold more Factor V (V.) activity; this increase was statistically significant (P < 0.05).
Previous studies with another atherogenic stimulus, homocysteine, indicated that activation ofendogenous Factor V, and not increased cellular concentration of Factor V, was associated with enhanced Factor X.-catalyzed prothrombin activation (4) . To determine whether vessel-wall Factor V was activated in the rabbit model of hypercholesterolemia, we studied the ability of Factor X. and control or hypercholesterolemic vessel segments to cleave '25I-prothrombin in an assay containing the thrombin inhibitor DAPA. The rationale for these experiments, based on earlier studies, is that prothrombin activation by endothelial cells and Factor X. requires thrombin to activate Factor V (4, 25). Fig. 2 -240 kD
To demonstrate directly the presence of a Factor V activator in atherosclerotic aorta, '25I-Factor V was incubated with vessel segments obtained from control or hypercholesterolemic rabbits. As shown in Fig. 3 Fig. 3 B. The Factor V. peptides produced by both atherogenic stimuli had very similar molecular weights.
To determine the contribution ofvascular endothelial cells to the increased vessel-wall Factor V activity, segments of control and atherosclerotic aorta were assayed for prothrombin activation before and after removal of the endothelium with a moist camel-hair brush. Removal of vascular endothehum from atherosclerotic aorta was associated with a 50% reduction in thrombin formation, while brushing of control vessel segments abolished thrombin formation (Fig. 4) (Fig. 6 ), which clearly demonstrated that the antihuman Factor V IgG cross-reacted with rabbit Factor V. To assess the distribution of Factor V in atherosclerotic aorta, immunocytochemistry was performed using IgG from a patient with an autoantibody to Factor V. Factor V antigen (indicated as black peroxidase reaction product) was observed in both control (Fig. 7 B) and atherosclerotic aortic segments (Fig. 7 D) . In control aorta, peroxidase reaction product was confined to the endothelium, whereas in atherosclerotic aorta, reaction product was also observed deeper within the intimal plaque. Preincubation of the anti-human Factor V IgG with purified human Factor V prevented the peroxidase reaction in both control and atherosclerotic segments (Fig. 7, A contribution of each cell type to the Factor V observed in our immunocytochemistry studies has not been determined. Effects of purified lipoproteins on adult bovine aortic endothelial cell Factor V activity. To determine whether lipoproteins known to be increased in hypercholesterolemic plasma might mediate increased vessel-wall Factor V activity, purified native LDL and j3-VLDL, as well as purified acetoacetylated LDL (5-60 Mg of protein/ml), were incubated with cultured ABAE cells for 3, 6, 9, 24, and 48 h. These purified lipoproteins did not affect Factor V activity in ABAE cells (data not shown).
Discussion
The data in this report indicate that rabbit vascular tissue expresses Factor V activity. Both control and atherosclerotic aorta from hypercholesterolemic rabbits possessed Factor V activity, which resulted in Factor Xa-catalyzed prothrombin activation. Aorta from hypercholesterolemic animals expressed higher levels of activity than aorta from animals fed a normal diet. Increased Factor X.-catalyzed prothrombin activation was first observed 4-5 wk after initiation of the highcholesterol diet. Aorta from animals on the diet 12-16 wk exhibited a ninefold increase in thrombin formation compared with control vessels. Punch biopsy specimens from atherosclerotic aorta yielded three-to fourfold increases in Factor V activity. One possible explanation for intact vessels exhibiting more coagulant activity than the punch biopsy samples might be that Factor V is a labile protein that may be inactivated during the freeze-thaw procedures used in the biopsy assays. Similar data were observed with cultured aortic endothelial cells treated with homocysteine; lysates of treated cells exhibited a fourfold increase in Factor V activity, while intact cells enhanced Factor Xa-catalyzed prothrombin activation 9-to 10-fold (4 (37) . Factor V antigen was not detected in smooth muscle cells of control vessels (Fig. 7) . Therefore (39) . Immunoreactive material was found only in the 5-8 ,m of lesion adjacent to the endothelium. In our studies (Fig. 7) , Factor V was observed throughout the lesions to a depth of -1,400Mum. Therefore, some of the peroxidase staining in our experiments may represent increased vascular permeability. However, it is unlikely that the Factor V antigen found so much deeper within the lesion resulted solely from increased vascular permeability. Another possibility would be that cells within the atherosclerotic lesion (vascular smooth muscle cells and macrophages) also contributed to this Factor V antigen.
We have previously reported that incubation of cultured vascular endothelial cells with the atherogenic metabolite homocysteine-activated endogenous Factor V (4). The components of hypercholesterolemic plasma responsible for mediating the increased vessel-wall Factor V activity observed in the present study are unknown. Incubation of the atherogenic lipoproteins (LDL, acetoacetylated LDL, and #l-VLDL) with cultured aortic endothelial cells failed to increase endogenous Factor V activity, even though cultured endothelial cells have receptors for these lipoproteins (9, 10) and even though these lipoproteins can be cytotoxic to cultured cells (40, 41) . How erosclerotic, but not by control vessel segments are more consistent with the hypothesis of Factor V activation. Nonetheless, both mechanisms may be operative in this model.
The '25I-Factor V. peptides produced by atherosclerotic aortic segments have apparent molecular weights very similar to those generated by homocysteine-treated aortic endothelial cells (Fig. 3 B) . These data suggest that both atherogenic stimuli, homocysteine and hypercholesterolemia, induce activation of Factor V by a similar mechanism, perhaps by a similar tissue protease. If this is the mechanism, previous studies with thrombin inhibitors in cultured endothelial cells (4) , as well as the present data with DAPA (Fig. 2) In the hypercholesterolemic animals, increased Factor V activity may lead to increased production of thrombin. Increased amounts ofthrombin may contribute to atherogenesis, since thrombin has been shown to be both chemotactic and mitogenic for monocytes (13, 14) . Thrombin has 'also been shown to cause endothelial cell retraction (15) and generation of platelet-derived growth factor (PDGF)-like mitogenic activity (16) . The optimal concentration ofthrombin required for these effects is 1-10 nM (0.1-1 U/ml) (13, 14, 16), an amount that the vessel wall or cultured vascular cells could generate (27) .
Other investigators have observed evidence of thrombinlike activity in human atherosclerotic lesions. Shainoff and Page described the deposition of a modified fibrinogen species within the aortic intima of atherosclerotic vascular tissue (47) . This modified fibrinogen'had the solubility characteristics of a stabilized clot, but a fibrinopeptide content consistent with fibrinogen. The exact nature of this protein is uncertain. More recently, immunocytochemistry studies using MAbs specific for fibrin determinants have identified fibrin that is presumably derived from thrombin cleavage of fibrinogen within atherosclerotic human vascular tissue (48) .
In the initial response-to-injury hypothesis (49), Ross and Harker proposed that the atherosclerotic lesion resulted from smooth muscle cell proliferation; this hypothesis required PDGF secretion from platelets adherent to denuded endothelium. However, such denuding endothelial cell injuries have not been demonstrated to occur before the development ofthe atherosclerotic lesion. A recent modification ofthis hypothesis (1) proposed that subtler endothelial cell perturbation is sufficient to initiate atherogenesis. In this model, perturbed endothelial cells would secrete PDGF, initiating smooth muscle cell proliferation (1) . Our data would be compatible with this mechanism, in that thrombin generation resulting from perturbed endothelium may be sufficient to initiate mitogen secretion and other critical events in atherogenesis.
Although there are differences in the pathogenesis of atherosclerosis in animal models and humans (17, 18, 50, 51) , the hypercholesterolemic rabbit model shares several features with the human vascular disorder. As recently reviewed by Ross (1) , examination of atherosclerotic lesions from several animal models, including hypercholesterolemic rabbits, revealed a cellular composition and histologic pattern similar to that observed in vessels from affected patients (52 
